AstraZeneca

Precision Medicine Market valued at USD 78.6 Billion in 2023, projected to reach USD 156.1 Billion by 2030, driven by technological advancements, rising chronic diseases, and collaborations. North America leads, followed by Europe and Asia-Pacific. Key players include AstraZeneca, Illumina, Johnson & Johnson, and Novartis.

AstraZeneca’s Imfinzi (durvalumab) granted Priority Review by FDA for muscle-invasive bladder cancer treatment, based on NIAGARA Phase III trial data showing reduced risk of disease progression, recurrence, and death. Imfinzi demonstrated a 32% reduction in risk of disease progression and a 25% reduction in risk of death compared to standard neoadjuvant chemotherapy.

Two studies show nirsevimab effectively protects infants from RSV, with no viral replacement. In a New York City study, 45% of infants received nirsevimab within their first 7 days of life.

Imfinzi (durvalumab) is a PD-L1 inhibitor used in various cancer treatments, including NSCLC, SCLC, biliary tract cancer, and endometrial cancer. AstraZeneca, a global biopharmaceutical company, focuses on oncology, rare diseases, and bio-pharmaceuticals, aiming to redefine cancer care and eliminate it as a cause of death.

FDA approves AstraZeneca’s Imfinzi for LS-SCLC treatment, supported by ADRIATIC trial results showing improved median overall survival of 22.5 months.

FDA approves AstraZeneca’s Imfinzi for limited-stage small cell lung cancer, showing significant survival and progression benefits in ADRIATIC trial.

The global precision medicine market was valued at USD 102.17 billion in 2024, expected to reach USD 470.53 billion by 2034, growing at a CAGR of 16.5%. Precision medicine involves personalized treatments based on genetic, environmental, and behavioral profiles. Key technologies include next-generation sequencing and bioinformatics. The U.S. leads with the NIH's 'All of Us Research Program' and collaborations like AstraZeneca's cancer research. AI tools like Tempus and Foundation Medicine enhance genomic analysis. Potential benefits include improved patient privacy, new data tools, and better FDA oversight. North America dominates the market, with Asia-Pacific expected to grow fastest due to strategic collaborations and government standards.

The global RNA-targeted small molecules market is projected to grow from USD 2,453.5 million in 2024 to USD 4,311.7 million by 2034, driven by increased R&D investments and the potential of RNA-targeted therapies in treating genetic and chronic diseases.

The RNA-targeted small molecules market is expected to grow from USD 2,453.5 million in 2024 to USD 4,311.7 million by 2034, driven by R&D investments and the potential of RNA-targeted therapies in genetic and chronic diseases. These therapies offer precision and adaptability, reshaping the pharmaceutical landscape with opportunities for innovation and growth.

The FDA approved AstraZeneca’s Imfinzi (durvalumab) for limited-stage small cell lung cancer (LS-SCLC) after platinum-based chemotherapy and radiation therapy. The approval was based on the Phase III ADRIATIC trial, which showed improved survival with Imfinzi, reducing the risk of death by 27% and achieving a median OS of 55.9 months. This marks the first systemic immunotherapy for LS-SCLC.